Journal Article

Effects of Omeprazole on Plasma Levels of Raltegravir

Marian Iwamoto, Larissa A. Wenning, Bach-Yen Nguyen, Hedy Teppler, Allison R. Moreau, Rand R. Rhodes, William D. Hanley, Bo Jin, Charlotte M. Harvey, Sheila A. Breidinger, Neal Azrolan, H. Frank Farmer, Robin D. Isaacs, Jeffery A. Chodakewitz, Julie A. Stone and John A. Wagner

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 48, issue 4, pages 489-492
Published in print February 2009 | ISSN: 1058-4838
Published online February 2009 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/596503
Effects of Omeprazole on Plasma Levels of Raltegravir

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with omeprazole coadministration in healthy subjects; this is likely secondary to an increase in bioavailability attributable to increased gastric pH. Increased gastric pH has been reported in HIV-1–infected individuals, and the effects of omeprazole in this intended population may be diminished. Further investigation is necessary.

Journal Article.  2146 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.